A Highly Potent and Selective PKCα Inhibitor Generated via Combinatorial Modification of a Peptide Scaffold

Journal of the American Chemical Society

Volumn 126, Issue 11, 2004, Pages 3394-3395

  Lee, Jung Hwan ^a   Nandy, Sandip K ^a   Lawrence, David S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C ALPHA; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; COMPETITIVE INHIBITION; CONSENSUS SEQUENCE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; INHIBITION KINETICS; PEPTIDE ANALYSIS;

ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; COMBINATORIAL CHEMISTRY TECHNIQUES; CONSENSUS SEQUENCE; ENZYME INHIBITORS; PEPTIDES; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 1642399144     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja037300b     Document Type: Article

References (22)

1. (a) Lam, K. S.; Liu, R.; Miyamoto, S.; Lehman, A. L.; Tuscano, J. M. Acc. Chem. Res. 2003, 36, 370-377.
2. (b) Cortese, R.; Monaci, P.; Nicosia, A.; Luzzago, A.; Felici, F.; Galfre, G.; Pessi, A.; Tramontano, A.; Sollazzo, M. Curr. Opin. Biotechnol. 1995, 6, 73-80.
3. (c) Dostmann, W. R.; Tegge, W.; Frank, R.; Nickl, C. K.; Taylor, M. S.; Brayden, J. E. Pharmacol. Ther. 2002, 93, 203-215.
4. (d) Chan, P. M.; Miller, W. T. Methods Mol. Biol. 1998, 84, 75-86.
5. (a) Yeh, R. H.; Lee, T. R.; Lawrence, D. S. Pharmacol. Ther. 2002, 93, 179-191.
6. (b) Yeh, R.-H., Lee, T. R. Lawrence, D. S. J. Biol. Chem. 2001, 276, 12235-12240.
7. (c) Shen, K.; Keng, Y.-F.; Wu, L.; Guo, X.-L.; Lawrence, D. S.; Zhang, Z.-Y. J. Biol. Chem. 2001, 276, 47311-47319.
8. (d) Lee, T. R.; Lawrence, D. S. J. Med. Chem. 1999, 42, 784-787.
9. For example, see: (a) Nguyen, J. T.; Porter, M.; Amoui, M.; Miller, W. T.; Zuckermann, R. N.; Lim, W. A. Chem. Biol. 2000, 7, 463-473.
10. (b) Feng, S.; Kapoor, T. M.; Shirai, F.; Combs, A. P.; Schreiber, S. L. Chem. Biol. 1996, 3, 661-670.
11. Nakashima, S. J. Biochem. (Tokyo) 2002, 132, 669-675.
12. Majority of studies with peptide-based PKC inhibitors were performed with PKC mixtures: (a) Borowski, P.; Resch, K.; Schmitz, H.; Heiland, M. Biol. Chem. 2000, 381, 19-27.
13. (b) Ward, N. E.; Gravitt, K. R.; O'Brian, C. A. Cancer Lett. 1995, 88, 37-40.
14. (c) Eichholtz, T.; de Bont, D. B. A.; de Widt, J.; Liskamp, R. M. J.; Ploegh, H. L. J. Biol. Chem. 1993, 268, 1982-1986.
15. (d) O'Brian C. A.; Ward, N. E. Mol. Pharmacol. 1989, 36, 355-359.
16. (e) Ricouart, A.; Tartar, A.; Sergheraert, C. Biochem. Biophys. Res. Commun. 1989, 165, 1382-1909.
17. (f) Charp, P. A.; Rice, W. G.; Raynor, R. L.; Reimund, E.; Kinkade, J. M., Jr.; Ganz, T.; Selsted, M. E.; Leher, R. L.; Kuo, R. F. Biochem. Pharmacol. 1988, 37, 951-956.
18. (g) House, C.; Kemp, B. E. Science 1987, 238, 1726-1728.
19. Nishikawa, K.; Toker, A.; Johannes, F.-J.; Songyang, Z.; Cantley, L. C. J. Biol. Chem. 1997, 272, 952-960.
20. Lawrence, D. S.; Niu, J. Pharmacol. Ther. 1998, 77, 81-114.
21. (a) Way, K. J.; Chou, E.; King, G. L. TiPs 2000, 21, 181-187.
22. (b) Hofmann, J. FASEB J. 1997, 11, 649-669.